Detalhe da pesquisa
1.
A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: the lega trial.
Gastric Cancer
; 25(4): 783-793, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35352176
2.
The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia.
PLoS One
; 8(3): e58424, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23520509
3.
NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies.
Mol Cancer Ther
; 11(4): 1006-16, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22319201
4.
Therapeutic efficacy of the pan-cdk inhibitor PHA-793887 in vitro and in vivo in engraftment and high-burden leukemia models.
Exp Hematol
; 38(4): 259-269.e2, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-20167248